vs

Side-by-side financial comparison of Arrive AI Inc. (ARAI) and Monopar Therapeutics (MNPR). Click either name above to swap in a different company.

Arrive AI Inc. is the larger business by last-quarter revenue ($90.7K vs $73.5K, roughly 1.2× Monopar Therapeutics). Monopar Therapeutics runs the higher net margin — -2334.5% vs -4066.2%, a 1731.7% gap on every dollar of revenue.

Arrive AI Inc. develops and delivers AI-powered logistics and supply chain optimization solutions. Its core offerings include intelligent route planning, automated load matching, and operational efficiency tools targeted at e-commerce merchants, freight forwarders, and small-to-medium logistics operators across the North American market, helping cut operational costs and shorten delivery cycles.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for cancer patients. Its lead product candidates address unmet oncology medical needs, serving North American markets and partnering with global healthcare and research institutions to advance its development pipeline.

ARAI vs MNPR — Head-to-Head

Bigger by revenue
ARAI
ARAI
1.2× larger
ARAI
$90.7K
$73.5K
MNPR
Higher net margin
MNPR
MNPR
1731.7% more per $
MNPR
-2334.5%
-4066.2%
ARAI

Income Statement — Q2 FY2025 vs Q2 FY2024

Metric
ARAI
ARAI
MNPR
MNPR
Revenue
$90.7K
$73.5K
Net Profit
$-3.7M
$-1.7M
Gross Margin
Operating Margin
-4066.2%
-2434.5%
Net Margin
-4066.2%
-2334.5%
Revenue YoY
-42.7%
Net Profit YoY
22.0%
EPS (diluted)
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARAI
ARAI
MNPR
MNPR
Q2 25
$90.7K
Q2 24
$73.5K
Q1 24
$82.2K
Q4 23
$98.1K
Q3 23
$112.3K
Q2 23
$128.2K
Q1 23
$90.5K
Q4 22
$12.7K
Net Profit
ARAI
ARAI
MNPR
MNPR
Q2 25
$-3.7M
Q2 24
$-1.7M
Q1 24
$-1.6M
Q4 23
$-1.8M
Q3 23
$-2.0M
Q2 23
$-2.2M
Q1 23
$-2.4M
Q4 22
Operating Margin
ARAI
ARAI
MNPR
MNPR
Q2 25
-4066.2%
Q2 24
-2434.5%
Q1 24
-2097.5%
Q4 23
-1949.6%
Q3 23
-1840.4%
Q2 23
-1815.8%
Q1 23
-2790.5%
Q4 22
Net Margin
ARAI
ARAI
MNPR
MNPR
Q2 25
-4066.2%
Q2 24
-2334.5%
Q1 24
-1997.5%
Q4 23
-1849.6%
Q3 23
-1740.4%
Q2 23
-1715.8%
Q1 23
-2690.5%
Q4 22
EPS (diluted)
ARAI
ARAI
MNPR
MNPR
Q2 25
$-0.12
Q2 24
Q1 24
Q4 23
Q3 23
Q2 23
Q1 23
Q4 22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARAI
ARAI
MNPR
MNPR
Cash + ST InvestmentsLiquidity on hand
$6.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$4.5M
$6.1M
Total Assets
$8.5M
$7.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARAI
ARAI
MNPR
MNPR
Q2 25
Q2 24
$6.1M
Q1 24
$7.8M
Q4 23
$7.3M
Q3 23
$5.5M
Q2 23
$7.2M
Q1 23
$5.7M
Q4 22
$8.2M
Stockholders' Equity
ARAI
ARAI
MNPR
MNPR
Q2 25
$4.5M
Q2 24
$6.1M
Q1 24
$7.5M
Q4 23
$5.6M
Q3 23
$6.6M
Q2 23
$7.8M
Q1 23
$8.9M
Q4 22
$10.1M
Total Assets
ARAI
ARAI
MNPR
MNPR
Q2 25
$8.5M
Q2 24
$7.2M
Q1 24
$8.9M
Q4 23
$7.3M
Q3 23
$8.6M
Q2 23
$10.3M
Q1 23
$11.8M
Q4 22
$13.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARAI
ARAI
MNPR
MNPR
Operating Cash FlowLast quarter
$-3.3M
$-1.7M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARAI
ARAI
MNPR
MNPR
Q2 25
$-3.3M
Q2 24
$-1.7M
Q1 24
$-1.7M
Q4 23
$-1.5M
Q3 23
$-1.9M
Q2 23
$-2.1M
Q1 23
$-2.3M
Q4 22
$-7.2M

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons